<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VISKEN- pindolol tablet </strong><br>Novartis Pharmaceuticals Corporation<br></p></div>
<h1>Visken<span class="Sup">®</span>
</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First">T1999-39</p>
<p>89003701</p>
<p><br></p>
<p><span class="Bold">   Visken</span><span class="Bold"><span class="Sup">®</span></span></p>
<p><span class="Italics">   (pindolol)</span></p>
<p><span class="Italics">   tablets, USP</span></p>
<p><br></p>
<p><span class="Bold">   Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Visken<span class="Sup">®</span> (pindolol), a synthetic beta-adrenergic receptor blocking agent with intrinsic sympathomimetic activity is 1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol. </p>
<p><br></p>
<p>Its structural formula is:</p>
<p><br></p>
<p><br><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=07FE9CC3-1EF2-420C-B45D-7F1E894B6EF9&amp;name=visken-figure-02.jpg"></p>
<p><br></p>
<p>Pindolol is a white to off-white odorless powder soluble in organic solvents and aqueous acids. Visken<span class="Sup">®</span> (pindolol) is intended for oral administration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2><span class="Italics">5 mg and 10 mg Tablets</span></h2>
<p class="First"><span class="Italics">Active Ingredient:</span> pindolol</p>
<p><span class="Italics">Inactive Ingredients:</span> colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.</p>
<p><br></p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Visken<span class="Sup">®</span> (pindolol) is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5"></a><p></p>
<h1>PHARMACODYNAMICS</h1>
<p class="First">In standard pharmacologic tests in man and animals, Visken<span class="Sup">®</span> (pindolol) attenuates increases in heart rate, systolic blood pressure, and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> resulting from exercise and isoproterenol administration, thus confirming its beta-blocking properties. The ISA or partial agonist activity of Visken<span class="Sup">®</span> (pindolol) is mediated directly at the adrenergic receptor sites and may be blocked by other beta-blockers. In catecholamine-depleted animal experiments, ISA is manifested as an increase in the inotropic and chronotropic activity of the myocardium. In man, ISA is manifested by a smaller reduction in the resting heart rate (4-8 beats/min) than is seen with drugs lacking ISA. There is also a smaller reduction in resting <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>. The clinical significance of this observation has not been evaluated and there is no evidence, or reason to believe, that exercise <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> is less affected by Visken<span class="Sup">®</span> (pindolol).</p>
<p><br></p>
<p>Visken<span class="Sup">®</span> (pindolol) has been shown in controlled, double-blind clinical studies to be an effective antihypertensive agent when used as monotherapy, or when added to therapy with thiazide-type diuretics. Divided dosages in the range of 10-60 mg daily have been shown to be effective. As monotherapy, Visken<span class="Sup">®</span> (pindolol) is as effective as propranolol, α-methyldopa, hydrochlorothiazide, and chlorthalidone in reducing systolic and diastolic blood pressure. The effect on blood pressure is not orthostatic, i.e. Visken<span class="Sup">®</span> (pindolol) was equally effective in reducing the supine and standing blood pressure.</p>
<p><br></p>
<p>In open, long-term studies up to 4 years, no evidence of diminution of the blood pressure-lowering response was observed.</p>
<p><br></p>
<p>An average 3-pound increase in body weight has been noted in patients treated with Visken<span class="Sup">®</span> (pindolol) alone, a larger increase than was observed with propranolol or placebo. The <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> appeared unrelated to blood pressure response and was not associated with an increased risk of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, although <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was more common than in control patients. Visken<span class="Sup">®</span> (pindolol) does not have a consistent effect on plasma renin activity.</p>
<p><br></p>
<p>The mechanism of the antihypertensive effects of beta-blocking agents has not been established, but several mechanisms have been postulated: 1) an effect on the central nervous system resulting in a reduced sympathetic outflow to the periphery, 2) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic receptor sites, leading to decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, 3) an inhibition of renin release. These mechanisms appear less likely for pindolol than other beta-blockers in view of the modest effect on resting <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and renin.</p>
<p><br></p>
<p>Beta-blockade therapy is useful when it is necessary to suppress the effects of beta-adrenergic agonists in order to achieve therapeutic goals. However, in certain clinical situations, (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>), the preservation of an adequate sympathetic tone may be necessary to maintain vital functions. Although a beta-antagonist with ISA such as Visken<span class="Sup">®</span> (pindolol) does not eliminate sympathetic tone entirely, there is no controlled evidence that it is safer than other beta-blockers in such conditions as <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> or is less likely to cause those conditions. In single dose studies of the effects of beta-blockers on FEV<span class="Sub">1</span>, Visken<span class="Sup">®</span> (pindolol) was indistinguishable from other non-cardioselective agents in its reduction of FEV<span class="Sub">1</span>, and its reduction in the effectiveness of an exogenous beta agonist.</p>
<p><br></p>
<p>Exacerbation of angina and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and ventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Abrupt withdrawal of these agents in patients without <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> has resulted in transient symptoms, including <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremulousness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6"></a><p></p>
<h1>PHARMACOKINETICS AND METABOLISM</h1>
<p class="First">Visken<span class="Sup">®</span> (pindolol) is rapidly and reproducibly absorbed (greater than 95%), achieving peak plasma concentrations within 1 hour of drug administration. Visken<span class="Sup">®</span> (pindolol) has no significant first-pass effect. The blood concentrations are proportional in a linear manner to the administered dose in the range of 5-20 mg. Upon repeated administration to the same subject, variation is minimal. After a single dose, intersubject variation for peak plasma concentrations was about 4fold (e.g., 45-167 ng/mL for a 20 mg dose). Upon multiple dosing, intersubject variation decreased to 2-2.5 fold. Visken<span class="Sup">®</span> (pindolol) is only 40% bound to plasma proteins and is evenly distributed between plasma and red cells. The volume of distribution in healthy subjects is about 2 L/kg.</p>
<p><br></p>
<p>Visken<span class="Sup">®</span> (pindolol) undergoes extensive metabolism in animals and man. In man, 35%-40% is excreted unchanged in the urine and 60%-65% is metabolized primarily to hydroxy-metabolites which are excreted as glucuronides and ethereal sulfates. The polar metabolites are excreted with a half-life of approximately 8 hours and thus multiple dosing therapy (q.8H) results in a less than 50% accumulation in plasma. About 6%-9% of an administered intravenous dose is excreted by the bile into the feces.</p>
<p><br></p>
<p>The disposition of Visken<span class="Sup">®</span> (pindolol) after oral administration is monophasic with a half-life in healthy subjects or hypertensive patients with normal renal function of approximately 3-4 hours. Following t.i.d. administration (q.8H), no significant accumulation of Visken<span class="Sup">®</span> (pindolol) is observed.</p>
<p><br></p>
<p>In elderly hypertensive patients with normal renal function, the half-life of Visken<span class="Sup">®</span> (pindolol) is more variable, averaging about 7 hours, but with values as high as 15 hours.</p>
<p><br></p>
<p>In hypertensive patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal diseases</span>, the half-life is within the range expected for healthy subjects. However, a significant decrease (50%) in volume of distribution (V<span class="Sub">D</span>) is observed in uremic patients and V<span class="Sub">D</span> appears to be directly correlated to creatinine clearance. Therefore, renal drug clearance is significantly reduced in uremic patients, resulting in a significant decrease in urinary excretion of unchanged drug. Uremic patients with a creatinine clearance of less than 20 mL/min generally excreted less than 15% of the administered dose unchanged in the urine.</p>
<p><br></p>
<p>In patients with histologically diagnosed cirrhosis of the liver, the elimination of Visken<span class="Sup">®</span> (pindolol) was more variable in rate and generally significantly slower than in healthy subjects. The total body clearance of Visken<span class="Sup">®</span> (pindolol) in cirrhotic patients ranged from about 50-300 mL/min and was directly correlated to antipyrine clearance. The half-life ranges from 2.5 hours to greater than 30 hours. These findings strongly suggest that caution should be exercised in dosage adjustments of Visken<span class="Sup">®</span> (pindolol) in such patients.</p>
<p><br></p>
<p>The bioavailability of Visken<span class="Sup">®</span> (pindolol) is not significantly affected by co-administration of food, hydralazine, hydrochlorothiazide or aspirin. Visken<span class="Sup">®</span> (pindolol) has no effect on warfarin activity or the clinical effectiveness of digoxin, although small transient decreases in plasma digoxin concentrations were noted. </p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-7"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Visken<span class="Sup">®</span> (pindolol) is indicated in the management of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-8"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Visken<span class="Sup">®</span> (pindolol) is contraindicated in: 1) bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; 2) overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>; 3) <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>; 4) second and third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>; 5) severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.  </p>
<p><span class="Italics">(See WARNINGS)</span></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-9"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Sympathetic stimulation may be a vital component supporting circulatory function in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and its inhibition by beta-blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, if necessary, Visken<span class="Sup">®</span> (pindolol) can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>In Patients Without History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">In patients with latent <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac insufficiency</span>, continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can in some cases lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of impending <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, patients should be fully digitalized and/or be given a diuretic, and the response observed closely. If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> continues, despite adequate digitalization and diuretic, Visken<span class="Sup">®</span> (pindolol) therapy should be withdrawn (gradually if possible).</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Exacerbation of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span> Following Abrupt Withdrawal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have occurred after <span class="Italics">abrupt</span> discontinuation of such therapy. When discontinuing chronically administered Visken<span class="Sup">®</span> (pindolol), particularly in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, the dosage should be gradually reduced over a period of 1-2 weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, Visken<span class="Sup">®</span> (pindolol) administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> is common and may be unrecognized, it may be prudent not to discontinue Visken<span class="Sup">®</span> (pindolol) therapy abruptly even in patients treated only for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.4"></a><p></p>
<h2>Nonallergic <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>) - Patients with Bronchospastic Diseases Should in General Not Receive Beta-Blockers</h2>
<p class="First">Visken<span class="Sup">®</span> (pindolol) should be administered with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta<span class="Sub">2</span> receptors.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5"></a><p></p>
<h2>Major Surgery</h2>
<p class="First">Because beta blockade impairs the ability of the heart to respond to reflex stimuli and may increase the risks of general anesthesia and surgical procedures, resulting in protracted <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or low <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, it has generally been suggested that such therapy should be gradually withdrawn several days prior to surgery. Recognition of the increased sensitivity to catecholamines of patients recently withdrawn from beta-blocker therapy, however, has made this recommendation controversial. If possible, beta-blockers should be withdrawn well before surgery takes place. In the event of emergency surgery, the anesthesiologist should be informed that the patient is on beta-blocker therapy.</p>
<p><br></p>
<p>The effects of Visken<span class="Sup">®</span> (pindolol) can be reversed by administration of beta-receptor agonists such as isoproterenol, dopamine, dobutamine, or levarterenol. Difficulty in restarting and maintaining the heart beat has also been reported with beta-adrenergic receptor blocking agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and blood pressure changes) of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. This is especially important with labile diabetics. Beta-blockade also reduces the release of insulin in response to <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>; therefore, it may be necessary to adjust the dose of antidiabetic drugs.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-adrenergic blockade may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>.  Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-blockade which might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid crisis</span>.</p>
<p><br></p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-10"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Impaired Renal or Hepatic Function</h2>
<p class="First">Beta-blocking agents should be used with caution in patients with impaired hepatic or renal function. Poor renal function has only minor effects on Visken<span class="Sup">®</span> (pindolol) clearance, but poor hepatic function may cause blood levels of Visken<span class="Sup">®</span> (pindolol) to increase substantially.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-10.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients, especially those with evidence of coronary artery insufficiency, should be warned against interruption or discontinuation of Visken<span class="Sup">®</span> (pindolol) therapy without the physician’s advice. Although <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> rarely occurs in properly selected patients, patients being treated with beta-adrenergic blocking agents should be advised to consult the physician at the first sign or symptom of impending failure.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-10.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients receiving Visken<span class="Sup">®</span> (pindolol) plus a catecholamine-depleting agent should, therefore, be closely observed for evidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> which may produce <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
<p><br></p>
<p>Visken<span class="Sup">®</span> (pindolol) has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.</p>
<p><br></p>
<p>Visken<span class="Sup">®</span> (pindolol) has been shown to increase serum thioridazine levels when both drugs are co-administered. Visken<span class="Sup">®</span> (pindolol) levels may also be increased with this combination.</p>
<p><br></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.1"></a><p></p>
<h3>Risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span>: </h3>
<p class="First">While taking beta blockers, patients with a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p><br></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In chronic oral toxicologic studies (1-2 years) in mice, rats, and dogs, Visken<span class="Sup">®</span> (pindolol) did not produce any significant toxic effects. In 2-year oral carcinogenicity studies in rats and mice in doses as high as 59 mg/kg/day and 124 mg/kg/day (50 and 100 times the maximum recommended human dose), respectively, Visken<span class="Sup">®</span> (pindolol) did not produce any neoplastic, preneoplastic, or nonneoplastic pathologic lesions. In fertility and general reproductive performance studies in rats, Visken<span class="Sup">®</span> (pindolol) caused no adverse effects at a dose of 10 mg/kg.</p>
<p><br></p>
<p>In the male fertility and general reproductive performance test in rats, definite toxicity characterized by mortality and decreased <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was observed in the group given 100 mg/kg/day. At 30 mg/kg/day, decreased mating was associated with <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> and/or decreased spermatogenesis. This response is not clearly drug related, however, as there was no dose response relationship within this experiment and no similar effect on testes of rats administered Visken<span class="Sup">®</span> (pindolol) as a dietary admixture for 104 weeks. There appeared to be an increase in prenatal mortality in males given 100 mg/kg but development of offspring was not impaired.</p>
<p><br></p>
<p>In females administered Visken<span class="Sup">®</span> (pindolol) prior to mating through day 21 of lactation, mating behavior was decreased at 100 mg/kg and 30 mg/kg. At these dosages there also was increased mortality of offspring. Prenatal mortality was increased at 10 mg/kg but there was not a clear dose response relationship in this experiment. There was an increased resorption rate at 100 mg/kg observed in females necropsied on the 15th day of gestation.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-10.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.5.1"></a><p></p>
<h3>Category B: </h3>
<p class="First">Studies in rats and rabbits exceeding 100 times the maximum recommended human doses, revealed no embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. Since there are no adequate and well-controlled studies in pregnant women, and since animal reproduction studies are not always predictive of human response, Visken<span class="Sup">®</span> (pindolol), as with any drug, should be employed during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><br></p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-10.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Since Visken<span class="Sup">®</span> (pindolol) is secreted in human milk, nursing should not be undertaken by mothers receiving the drug.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-10.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>CLINICAL LABORATORY</h1>
<p class="First">Minor persistent elevations in serum transaminases (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT) have been noted in 7% of patients during Visken<span class="Sup">®</span> (pindolol) administration, but progressive elevations were not observed. These elevations were not associated with any other abnormalities that would suggest <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, such as decreased serum albumin and total proteins. During more than a decade of worldwide marketing, there have been no reports in the medical literature of overt hepatic injury. Alkaline phosphatase, lactic acid dehydrogenase (LDH), and uric acid are also elevated on rare occasions. The significance of these findings is unknown.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-12"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Most adverse reactions have been mild. The incidences listed in the following table are derived from 12-week comparative double-blind, parallel design trials in hypertensive patients given Visken<span class="Sup">®</span> (pindolol) as monotherapy, given various active control drugs as monotherapy, or given placebo. Data for Visken<span class="Sup">®</span> (pindolol) and the positive controls were pooled from several trials because no striking differences were seen in the individual studies, with 1 exception. When considering all adverse reactions reported, the frequency of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was noticeably higher in positive control trials [16% Visken<span class="Sup">®</span> (pindolol) vs. 9% positive control] than in placebo controlled trials [6%Visken<span class="Sup">®</span> (pindolol) vs. 3% placebo]. The table includes adverse reactions either volunteered or elicited, and at least possibly drug related, which were reported in greater than 2% of Visken<span class="Sup">®</span> (pindolol) patients and other selected important reactions.</p>
<table>
<caption><span>Adverse Reactions Which Were Volunteered or Elicited(and at least possibly drug related)</span></caption>
<thead><tr class="First Last">
<td align="center" valign="bottom">
<span class="Bold">Body System/</span><span class="Bold"><br><br>Adverse Reactions</span>
</td>
<td align="center" valign="bottom">
<span class="Bold">Visken</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> </span><span class="Bold"><br><br>(pindolol) </span><span class="Bold"><br><br>(N=322) </span><span class="Bold"><br><br>%</span>
</td>
<td align="center" valign="bottom">
<span class="Bold">Active </span><span class="Bold"><br><br>Controls* </span><span class="Bold"><br><br>(N=188) </span><span class="Bold"><br><br>%</span>
</td>
<td align="center" valign="bottom">
<span class="Bold">Placebo </span><span class="Bold"><br><br>(N=78) </span><span class="Bold"><br><br>%</span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" valign="bottom"><br></td>
<td class="Toprule" align="center" valign="bottom"><br></td>
<td class="Toprule" align="center" valign="bottom"><br></td>
<td class="Toprule" align="center" valign="bottom"><br></td>
</tr>
<tr>
<td valign="bottom">Central Nervous System</td>
<td align="center" valign="bottom"><br></td>
<td align="center" valign="bottom"><br></td>
<td align="center" valign="bottom"><br></td>
</tr>
<tr>
<td valign="bottom">   Bizarre or Many Dreams</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">6</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="right">9</td>
<td align="right">11</td>
<td align="right">1</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">4</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span></td>
<td align="right">&lt;1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="right">10</td>
<td align="right">3</td>
<td align="right">10</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">5</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td valign="bottom">Autonomic Nervous System</td>
<td align="right"><br></td>
<td align="right"><br></td>
<td align="right"><br></td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">6</td>
</tr>
<tr>
<td valign="bottom">Cardiovascular</td>
<td align="right"><br></td>
<td align="right"><br></td>
<td align="right"><br></td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">6</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></td>
<td align="right">&lt;1</td>
<td align="right">&lt;1</td>
<td align="right">0</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td align="right">&lt;1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td valign="bottom">Musculoskeletal</td>
<td align="right"><br></td>
<td align="right"><br></td>
<td align="right"><br></td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">3</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint Pain</span></td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">4</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Cramps</span></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle Pain</span></td>
<td align="right">10</td>
<td align="right">9</td>
<td align="right">8</td>
</tr>
<tr>
<td valign="bottom">Gastrointestinal</td>
<td align="right"><br></td>
<td align="right"><br></td>
<td align="right"><br></td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal Discomfort</span></td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">5</td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td valign="bottom">Skin</td>
<td align="right"><br></td>
<td align="right"><br></td>
<td align="right"><br></td>
</tr>
<tr>
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="right">1</td>
<td align="right">&lt;1</td>
<td align="right">0</td>
</tr>
<tr class="Last">
<td valign="bottom">   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="right">&lt;1</td>
<td align="right">&lt;1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p><span class="Sup">*</span>Active Controls: Patients received either propranolol, α-methyldopa or a diuretic (hydrochlorothiazide or chlorthalidone).</p>
<p><br></p>
<p>The following selected (potentially important) adverse reactions were seen in 2% or fewer patients and their relationship to Visken<span class="Sup">®</span> (pindolol) is uncertain. CENTRAL NERVOUS SYSTEM: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>; AUTONOMIC NERVOUS SYSTEM: <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>; CARDIOVASCULAR: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span>, <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold extremities</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>; GASTROINTESTINAL: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; RESPIRATORY: <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>; UROGENITAL: <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>; MISCELLANEOUS: eye <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> or <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">burning eyes</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1>POTENTIAL ADVERSE EFFECTS</h1>
<p class="First">In addition, other adverse effects not aforementioned have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects of Visken<span class="Sup">®</span> (pindolol).</p>
<p><br></p>
<p><span class="Bold Italics">Central Nervous System</span>: Reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>; an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium, and decreased performance on neuropsychometrics.</p>
<p><br></p>
<p><span class="Bold Italics">Cardiovascular</span>: Intensification of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>.  <span class="Italics">(See CONTRAINDICATIONS)</span></p>
<p><br></p>
<p><span class="Bold Italics">Allergic</span>: Erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>; <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>; <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>.</p>
<p><br></p>
<p><span class="Bold Italics">Hematologic</span>: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>; thrombocytopenic and nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
<p><br></p>
<p><span class="Bold Italics">Gastrointestinal</span>: Mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>; <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>.</p>
<p><br></p>
<p><span class="Bold Italics">Miscellaneous</span>: Reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>; Peyronie’s disease.</p>
<p><br></p>
<p>The <span class="product-label-link" type="condition" conceptid="4317263" conceptname="Ocular-mucous membrane syndrome">oculomucocutaneous syndrome</span> associated with the beta-blocker practolol has not been reported with Visken<span class="Sup">®</span> (pindolol) during investigational use and extensive foreign experience amounting to over 4 million patient-years.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-14"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No specific information on emergency treatment of overdosage is available. Therefore, on the basis of the pharmacologic actions of Visken<span class="Sup">®</span> (pindolol), the following general measures should be employed as appropriate in addition to gastric lavage:</p>
<p><br></p>
<p><span class="Bold Italics">Excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></span>: administer atropine; if there is no response to vagal blockade, administer isoproterenol cautiously.</p>
<p><br></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></span>: digitalize the patient and/or administer diuretic. It has been reported that glucagon may be useful in this situation.</p>
<p><br></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span>: administer vasopressors, e.g., epinephrine or levarterenol, with serial monitoring of blood pressure. (There is evidence that epinephrine may be the drug of choice.)</p>
<p><br></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></span>: administer a beta<span class="Sub">2</span> stimulating agent such as isoproterenol and/or a theophylline derivative.</p>
<p><br></p>
<p>A case of an acute overdosage has been reported with an intake of 500 mg of Visken<span class="Sup">®</span> (pindolol) by a hypertensive patient. <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">Blood pressure increased</span> and heart rate was ≥80 beats/min. Recovery was uneventful. In another case, 250 mg of Visken<span class="Sup">®</span> (pindolol) was taken with 150 mg diazepam and 50 mg nitrazepam, producing <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The patient recovered in 24 hours.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-15"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dosage of Visken<span class="Sup">®</span> (pindolol) should be individualized. The recommended initial dose of Visken<span class="Sup">®</span> (pindolol) is 5 mg b.i.d. alone or in combination with other antihypertensive agents. An antihypertensive response usually occurs within the first week of treatment. Maximal response, however, may take as long as or occasionally longer than 2 weeks. If a satisfactory reduction in blood pressure does not occur within 3-4 weeks, the dose may be adjusted in increments of 10 mg/day at these intervals up to a maximum of 60 mg/day.</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-16"></a><p></p>
<h1>HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<h2>Visken<span class="Sup">®</span> (pindolol) tablets, USP</h2>
<p class="First">White, uncoated, heart-shaped tablets; 5 mg and 10 mg, packages of 100. 5 mg tablets engraved “VISKEN 5’’ on one side, and embossed “V’’ on other side (NDC 0078-0111-05). 10 mg tablets engraved “VISKEN 10’’ on one side, and embossed “V’’ on other side (NDC 0078-0073-05).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<h2><span class="Italics">Store and Dispense </span></h2>
<p class="First">Below 86°F (30°C); tight, light-resistant container.</p>
<p><br></p>
<p>Manufactured by:</p>
<p>Novartis Pharmaceuticals Canada Inc.</p>
<p>Dorval (Quebec) Canada H9R 4P5</p>
<p><br></p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corporation</p>
<p>East Hanover, New Jersey  07936</p>
<p><br></p>
<p>REV:  NOVEMBER 1998                           T1999-39</p>
<p>89003701</p>
<p>2162-25-99A</p>
<p><br></p>
<p>©1998 Novartis</p>
<p><br></p>
<p><br></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VISKEN 		
					</strong><br><span class="contentTableReg">pindolol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0111</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>pindolol</strong> (pindolol) </td>
<td class="formItem"></td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>pregelatinized starch</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">VISKEN;5;V</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0111-05</td>
<td class="formItem">100  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VISKEN 		
					</strong><br><span class="contentTableReg">pindolol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0073</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>pindolol</strong> (pindolol) </td>
<td class="formItem"></td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>pregelatinized starch</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">VISKEN;10;V</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0073-05</td>
<td class="formItem">100  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novartis Pharmaceuticals Corporation</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>07FE9CC3-1EF2-420C-B45D-7F1E894B6EF9</div>
<div>Set id: 07FE9CC3-1EF2-420C-B45D-7F1E894B6EF9</div>
<div>Version: 1</div>
<div>Effective Time: 20061031</div>
</div>
</div> <div class="DistributorName">Novartis Pharmaceuticals Corporation</div></p>
</body></html>
